Table 3:
Pathways altered by PCB126 treatment of preadipocytes at the 1-Day timepoint (top 25, Fdr≤0.05).
| Pathway | pv_fdr |
|---|---|
| Cytokine-cytokine receptor interaction | 1.58E-06 |
| Viral protein interaction with cytokine and cytokine receptor | 1.58E-06 |
| AGE-RAGE signaling pathway in diabetic complications | 8.53E-05 |
| TNF signaling pathway | 0.000369 |
| Steroid biosynthesis | 0.000369 |
| Cell cycle | 0.000369 |
| Ovarian steroidogenesis | 0.000369 |
| Rheumatoid arthritis | 0.000393 |
| MAPK signaling pathway | 0.000499 |
| Neuroactive ligand-receptor interaction | 0.000775 |
| Pathways in cancer | 0.000813 |
| Malaria | 0.00103 |
| Oocyte meiosis | 0.001369 |
| NF-kappa B signaling pathway | 0.004984 |
| African trypanosomiasis | 0.005584 |
| IL-17 signaling pathway | 0.006917 |
| Amoebiasis | 0.006938 |
| Fluid shear stress and atherosclerosis | 0.010475 |
| PPAR signaling pathway | 0.011545 |
| Hematopoietic cell lineage | 0.012131 |
| Progesterone-mediated oocyte maturation | 0.012322 |
| Fanconi anemia pathway | 0.012322 |
| Rap1 signaling pathway | 0.012322 |
| Cholesterol metabolism | 0.012322 |
| Osteoclast differentiation | 0.013481 |